Impact of Continuous Flow Left Ventricular Assist Device on the Pharmacodynamic Response to Warfarin Early after Implantation

Abstract

Get full access to this article

View all access options for this article.

References

Rose

, Gelijns

, Moskowitz

, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345: 1435–43.

Slaughter

, Rogers

, Milano

, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361: 2241–51.

Kirklin

, Naftel

, Kormos

, et al. The Fourth INTERMACS Annual Report: 4,000 implants and counting. J Heart Lung Transplant 2012; 31: 117–26.

Stevenson

, Pagani

, Young

, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009; 28: 535–41.

Witt

, Delate

, Clark

, et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood 2009; 114: 952–6.

Jennings

, McDonnell

, Schillig

. Assessment of long-term anticoagulation in patients with a continuous-flow left-ventricular assist device: a pilot study. J Thorac Cardiovasc Surg 2011; 142: e1–2.

Boyle

, Russel

, Teuteberg

, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant 2009; 28: 881–7.